在急性心力衰竭中尿液增强策略
Tariq Jamal Siddiqi1, Milton Packer2, Justin A Ezekowitz3
1Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA.
JACC. Heart failure
|January 8, 2025
概括
急性心力衰竭 (AHF) 的利尿策略显示了各种短期症状缓解,但没有证实的长期益处. 强化循环利尿剂可能会缓解堵塞,但需要进一步的研究以获得最佳的AHF管理.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 急性心力衰竭 (AHF) 的管理通常涉及尿液策略.
- 优化脱塞对于改善AHF患者的治疗结果至关重要.
研究的目的:
- 总结各种利尿剂组合策略对AHF症状,征兆和生理变量的影响.
- 评估不同利尿剂方法对AHF患者短期和长期结果的影响.
主要方法:
- 12项随机对照试验的系统审查和元分析.
- 试验评估了将 thiazide 利尿剂, SGLT2 抑制剂, MRA, V1 抗剂, CA 抑制剂或强化循环利尿剂添加到传统的 AHF 治疗中.
主要成果:
- 短期反应,包括呼吸障碍缓解和体重变化,在利尿剂策略中不一致.
- 所有评估的利尿剂策略都与血清肌素的暂时增加有关.
- 对于任何策略的死亡率或复发性心力衰竭事件,没有观察到显著的益处.
结论:
- 循环利尿剂的强化可能会减轻AHF中拥堵的身体症状.
- 不同的短期解堵策略的长期影响和比较有效性仍未确定.
- 需要进一步的研究来确定最佳的利尿剂策略,以改善AHF的健康状况和长期结果.
相关概念视频
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Heart Failure Drugs: Inotropic Agents
515
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
515
Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
Antihypertensive Drugs: Potassium-Sparing Diuretics
445
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
445
Antihypertensive Drugs: Action of Diuretics
617
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
617


